XTL BiopharmaceuticalsXTLB -0.58%24 Market Cap is $5.67 Mil as of Jun. 26, 2026. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 89.8% on this metric.
XTL Biopharmaceuticals's quarterly market cap
increased
from Jun. 2024 ($13.24 Mil) to Dec. 2024 ($17.85 Mil) but then
declined
from Dec. 2024 ($17.85 Mil) to Jun. 2025 ($10.05 Mil).
XTL Biopharmaceuticals's annual market cap
declined
from Dec. 2022 ($6.59 Mil) to Dec. 2023 ($5.50 Mil) but then
increased
from Dec. 2023 ($5.50 Mil) to Dec. 2024 ($17.85 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. XTL Biopharmaceuticals's Enterprise Value for Today is $5.49 Mil.
XTL Biopharmaceuticals (NAS:XTLB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XTL Biopharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
XTL Biopharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a Market Cap of $5.67 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #1285 out of 1431 companies in the Biotechnology industry, placing it in the top 89.8%.
Is XTL Biopharmaceuticals' Market Cap too high?
XTL Biopharmaceuticals' current Market Cap is $5.67 Mil. The Biotechnology industry median Market Cap is 113.83. XTL Biopharmaceuticals' value of $5.67 Mil is 95% below this industry median. Based on the distribution chart, XTL Biopharmaceuticals ranks #1285 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #1285 out of 1431 companies for Market Cap. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median Market Cap is 113.83. XTL Biopharmaceuticals' value of $5.67 Mil is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XTL Biopharmaceuticals's current Market Cap of $5.67 Mil is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on XTL Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current Market Cap is $5.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Market Cap of $5.67 Mil. The current Market Cap is $5.67 Mil and 95% below the Biotechnology industry median of 113.83. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Market Cap is $5.67 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score
Get the complete analysis for XTLB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
